O Shaughnessy Asset Management LLC Boosts Stake in IDEXX Laboratories, Inc. $IDXX

O Shaughnessy Asset Management LLC increased its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 16.8% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 25,672 shares of the company’s stock after purchasing an additional 3,685 shares during the period. O Shaughnessy Asset Management LLC’s holdings in IDEXX Laboratories were worth $17,368,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Virtus Advisers LLC purchased a new stake in shares of IDEXX Laboratories in the 3rd quarter valued at about $26,000. Park Place Capital Corp purchased a new stake in IDEXX Laboratories during the 4th quarter valued at approximately $29,000. Mowery & Schoenfeld Wealth Management LLC raised its stake in IDEXX Laboratories by 58.8% during the 4th quarter. Mowery & Schoenfeld Wealth Management LLC now owns 54 shares of the company’s stock valued at $37,000 after acquiring an additional 20 shares during the last quarter. Wormser Freres Gestion raised its stake in IDEXX Laboratories by 671.4% during the 4th quarter. Wormser Freres Gestion now owns 54 shares of the company’s stock valued at $37,000 after acquiring an additional 47 shares during the last quarter. Finally, WealthCollab LLC purchased a new stake in IDEXX Laboratories during the 2nd quarter valued at approximately $30,000. 87.84% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have commented on IDXX shares. UBS Group reduced their price objective on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a research note on Tuesday, April 28th. Wall Street Zen downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Weiss Ratings downgraded IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, May 11th. Stifel Nicolaus cut their target price on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research note on Tuesday, March 31st. Finally, Citigroup started coverage on IDEXX Laboratories in a research note on Wednesday, April 15th. They set a “neutral” rating and a $650.00 target price for the company. Seven research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $751.00.

IDEXX Laboratories Stock Performance

IDXX opened at $578.89 on Wednesday. The stock has a market cap of $45.66 billion, a P/E ratio of 42.63, a P/E/G ratio of 3.07 and a beta of 1.55. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.12 and a quick ratio of 0.82. The stock’s 50 day simple moving average is $563.22 and its 200 day simple moving average is $630.28. IDEXX Laboratories, Inc. has a 1-year low of $506.91 and a 1-year high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, topping analysts’ consensus estimates of $3.41 by $0.06. The business had revenue of $1.14 billion for the quarter, compared to analysts’ expectations of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The company’s revenue was up 14.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.91 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, equities analysts anticipate that IDEXX Laboratories, Inc. will post 14.68 EPS for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.